Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network

European Journal of Haematology

Volumn 94, Issue 4, 2015, Pages 336-342

  Tsouana, Eva ^a   Kaya, Banu ^a   Gadong, Nimze ^b   Hemmaway, Claire ^c   Newell, Heather ^a   Simmons, Andrea ^a   Whitmarsh, Simon ^d   Telfer, Paul ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chelation; Deferasirox; Iron overload; Sickle cell disease

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; DEFERASIROX; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; CHILD; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRY WEIGHT; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBINOPATHY; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER IRON CONCENTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; TASTE DISORDER; TOXIC HEPATITIS; TREATMENT DURATION; UNITED KINGDOM; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; BLOOD; CLINICAL TRIAL; COMPLICATION; KIDNEY FUNCTION TEST; LIVER; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME;

ADOLESCENT; ALANINE TRANSAMINASE; ANEMIA, SICKLE CELL; BENZOATES; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY FUNCTION TESTS; LIVER; LONDON; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84925441832     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12435     Document Type: Article

References (11)

1. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8.
2. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154:387-97.
3. Kwiatkowski JL, Cohen AR, Garro J, et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol 2012;87:221-3.
4. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012;119:3925-32.
5. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66.
6. Raphael JL, Bernhardt MB, Mahoney DH, Mueller BU. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 2009;52:616-20.
7. Cancado R, Olivato MC, Bruniera P, Szarf G, de Moraes Bastos R, Rezende Melo M, Chiattone C. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. Acta Haematol 2012;128:113-8.
8. Voskaridou E, Plata E, Douskou M, Sioni A, Mpoutou E, Christoulas D, Dimopoulou M, Terpos E. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/beta-thalassemia. Ann Hematol 2011;90:11-5.
9. Alvarez O, Rodriguez-Cortes H, Robinson N, Lewis N, Pow Sang CD, Lopez-Mitnik G, Paley C. Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. J Pediatr Hematol Oncol 2009;31:739-44.
10. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-65.
11. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;118:884-93.